

SIXTEENTH CONGRESS OF THE REPUBLIC)
OF THE PHILIPPINES)
Second Regular Session)



Senate
Office of the Secretary

'15 JUN -8 P4 :22

SENATE
S. No. 2818

RECEIVED BY: _____

Introduced by Senator Miriam Defensor Santiago

AN ACT
TO REQUIRE MANUFACTURERS OR LABELERS OF PRESCRIPTION DRUGS TO
REPORT THEIR ANNUAL MARKETING COSTS

EXPLANATORY NOTE

The Constitution, Article 2, Section 5 provides:

Section 5. The maintenance of peace and order, the protection of life, liberty, and property, and promotion of the general welfare are essential for the enjoyment by all the people of the blessings of democracy.

Article 2, Section 15, on the other hand, provides:

Section 15. The State shall protect and promote the right to health of the people and instill health consciousness among them.

The cost of medicines in the Philippines is among the highest in the world. A study shows that it would take a full six days of wages for an average worker to purchase basic medicines in the country. There are more than 17,000 registered drugs in the local market, but a majority of the population can barely afford these expensive essential drugs.¹

According to the same news article, lawmakers are bewildered why Norvasc, a medicine for hypertension, is sold in the Philippines by a multinational pharmaceutical company for 41.41 pesos (US\$1) per 5-mg tablet; while in India and Pakistan, the same drug manufactured by the same company is priced at around 5.77 pesos (US\$.14). Plendil, also for hypertension, is priced in the Philippines at 21.82 pesos (US\$.54) per tablet while it costs only 2.69 pesos (US\$.07) in India. A Ventolin inhaler for asthma

patients is sold for 3 15.00 pesos (nearly US\$8) in the local market while in India it costs only 126.78 pesos (US\$3). Other medicines also show the same disparity. Ponstan, a common painkiller, costs only 3.22 pesos (US\$.05) in India but costs 24.92 pesos (US\$.60) per pill in the Philippines. Bactrim 400, priced at 17.75 pesos (US\$.40) per tablet in the Philippines, can be bought for only 1 peso (US\$.02) in Pakistan and 0.69 centavos in India (less than US\$.01).

In a US study, two significant factors contributing to the increase in drug costs are the large annual profits of drug companies and the costs in promotional spending by pharmaceutical manufacturers. Drug companies, however, argue that prices are high due to the high cost of research and development (R&D). However, according to the Kaiser Family Foundation, since 1996 promotional spending by drug manufacturers in the US has increased by 60 percent. Promotional spending by drug manufacturers includes paying for television commercials, giving free drug samples to physicians, and taking physicians and their staffs on expensive trips.

The situation in the Philippines is no different. Drugs manufacturers spend millions of pesos in marketing expenses. In order to create policy decisions as regards the problem of high medicine costs, lawmakers should be informed of the current level of marketing costs in relation to total production cost of drug manufacturers. This bill aims to require drug manufacturers to submit annual reports of their marketing expenses to the Secretary of Health in order to fill in the information gap in the minds of our lawmakers.¹


MIRIAM DEFENSOR SANTIAGO
27

¹ This bill was originally filed in the Fourteenth Congress, First Regular Session, and refiled during the Fifteenth Congress, First Regular Session.

SIXTEENTH CONGRESS OF THE REPUBLIC)
OF THE PHILIPPINES)
Second Regular Session)



SENATE
Office of the Secretary

'15 JUN -8 P4 :22

SENATE
S. No. 2818

RECEIVED BY: J

Introduced by Senator Miriam Defensor Santiago

AN ACT
TO REQUIRE MANUFACTURERS OR LABELERS OF PRESCRIPTION DRUGS TO
REPORT THEIR ANNUAL MARKETING COSTS

*Be it enacted by the Senate and House of Representatives of the Philippines in
Congress assembled:*

1 SECTION 1. *Short Title.* – This Act shall be known as “Annual Marketing
2 Expenses Report for Drug Manufacturers Act.”

3 SECTION 2. *Declaration of Principles.* – The maintenance of peace and order, the
4 protection of life, liberty, and property, and promotion of the general welfare are essential
5 for the enjoyment by all the people of the blessings of democracy. In order to protect the
6 general welfare of the population as regards access to cheap medicines, it is the policy of
7 the state to inquire into the reasonability of marketing expenses of drug firms.

8 SECTION 3. *Definition of Terms.* – For purposes of this Act, the term:

9 (a) “Labeler” means any person or entity that receives a prescription drug from the
10 manufacturer or a wholesaler of such drug, and repackages such drug to be dispensed in
11 this country;

12 (b) “Manufacturer” means a manufacturer of prescription drugs dispensed in this
13 country, and shall include the subsidiary or affiliate of such manufacturer; and

14 (c) “Marketing” means advertising and promotional activities for prescription
15 drugs dispensed in this country including, but not limited to, those activities described in
16 this Act.

1 SECTION 4. *Reportorial Requirement.* – The Secretary of Health is authorized
2 and directed to require manufacturers or labelers of prescription drugs, which dispense
3 such drugs in this country and which employ, direct or utilize marketing representatives,
4 to report the marketing costs of each of its prescription drugs dispensed in this country.

5 SECTION 5. *Manner of Reporting.* – On or before February 1 of each year every
6 manufacturer and labeler shall file a report with the Department of Health on its
7 marketing activities conducted in the country. Such report shall be submitted in such
8 form and manner, and include the payment of such a fee as shall be determined by the
9 Secretary of Health. Each such report shall include the value, nature, purpose and
10 recipient of marketing expenses including, but not limited to:

11 (a) all expenses associated with advertising, marketing and direct promotion of
12 prescription drugs through radio, television, magazines, newspapers, direct mail and
13 telephone communications as they pertain to residents of e country;

14 (b) all expenses associated with educational or informational programs, materials
15 and seminars, and remuneration for promoting or participating in educational or
16 informational sessions, regardless of whether the manufacturer or labeler provides the
17 educational or informational sessions or materials,

18 (c) all expenses associated with food, entertainment and gifts valued at more than
19 ₱1,000.00 and anything provided to a health care professional for less than market value,

20 (d) all expenses associated with trips and travel for marketing purposes,

21 (e) all expenses associated with product samples, except for samples that will be
22 distributed free of charge to patients; and

23 (f) the aggregate cost of all employees and contractors of the manufacturer or
24 labeler who directly or indirectly engage in the advertising or promotional activities,
25 including all forms of payment to such employees and contractors.

1 The cost reported pursuant to this Act shall reflect only that portion of payment to
2 employees and contractors that pertains to activities within the country or to recipients of
3 the advertising or promotional activities who are residents of or are employed in this
4 country.

5 SECTION 6. *Exceptions.* – The following marketing expenses shall not be subject
6 to the reporting requirements of this subdivision:

7 (a) expenses of ₱1,000 or less;

8 (b) Reasonable compensation and reimbursement for expenses in connection with
9 a *bona fide clinical trial of a new vaccine, therapy or treatment; and*

10 (c) scholarships and reimbursement of expenses for attending a significant
11 educational, scientific or policy-making conference or seminar of a national, regional or
12 specialty medical or other professional association if the recipient of the scholarship is
13 chosen by the association sponsoring the conference or seminar.

14 SECTION 7. *Department Reports.* – Annually on or before November 30, the
15 Department of Health shall submit a report, providing information in aggregate form, on
16 prescription drug marketing expenses to both Houses of Congress. One year after the
17 passage of this Act and every two years thereafter, the Department of Health shall
18 provide a report to both Houses of Congress, providing information in aggregate form,
19 containing an analysis of the data submitted to the Department of Health, including the
20 scope of prescription drug marketing activities and expenses and their effect on the cost,
21 utilization and delivery of health care services and any recommendations with regard to
22 marketing activities of prescription drug manufacturers and labelers.

1 SECTION 8. *Violations.* – Any person who violates any provision of this Act shall
2 be punished with a penalty of ₱500,000.00. Subsequent violations shall be cause for the
3 revocation of the manufacturer’s or labeler’s permit to do business in the country.

4 SECTION 9. *Implementing Rules and Regulations.* - Six months after the passage
5 of this Act, the Secretary of Health shall promulgate the rules and regulations necessary
6 to implement the provisions of this Act.

7 SECTION 10. *Separability Clause.* - If any provision or part of this Act is held
8 invalid, the remainder of this Act shall not be affected thereby.

9 SECTION 11. *Repealing Clause.* - All laws, decrees, executive order or rules and
10 regulations inconsistent with this Act are hereby repealed or modified accordingly.

11 SECTION 12. *Effectivity Clause.* - This Act shall take effect 15 days after its
12 publication in the *Official Gazette* or two newspapers of general circulation.

Approved,

/tdp3Jun2015